Teleflex gains FDA nod for lung isolation device

Teleflex Medical ($TFX) nailed down 510(k) clearance for a surgical device designed to isolate and block the lung during thoracic surgical procedures.

The Pennsylvania medical device company says the Rusch EZ-Blocker disposable endobronchial blocker will help boost its competitive position in the space, joining the roster of a number of endotracheal and endobronchial products it offers. During thoracic surgery the device is designed to enable lung isolation and single lung ventilation, depending on how long of a procedure is necessary.

Teleflex is nurturing steady growth of its airway management device space. In August, Teleflex spent $276 million to acquire LMA International in Singapore, which sells devices designed to administer drugs into the larynx. Teleflex touted the deal as boosting its respiratory and anesthesia business.

Of course, as it focuses on respiratory and anesthesia devices, Teleflex has pulled back from other areas. Also in August, Teleflex sealed a deal to sell its OEM orthopedics business to Tecomet for $45.2 million.

- read the release

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.